| Literature DB >> 34532256 |
Yankang Cui1, Shaobo Zhang1, Chenkui Miao1, Chao Liang1, Xiaochao Chen1, Tao Yan1, Hengtao Bu1, Huiyu Dong1, Junchen Li1, Jie Li1, Zengjun Wang1, Bianjiang Liu1.
Abstract
BACKGROUND: Studies over the past decade have shown that long non-coding RNAs (lncRNAs) play an essential role in the tumorigenesis and progression of kidney renal clear cell carcinoma (KIRC). Meanwhile, autophagy has been demonstrated to regulate KIRC pathogenesis and targeting therapy resistance. However, the prognostic value of autophagy-related lncRNAs in KIRC patients has not been reported before.Entities:
Keywords: Kidney renal clear cell carcinoma (KIRC); autophagy; immune; lncRNA; prognosis
Year: 2021 PMID: 34532256 PMCID: PMC8421821 DOI: 10.21037/tau-21-278
Source DB: PubMed Journal: Transl Androl Urol ISSN: 2223-4683
Figure 1Main workflow for the study. TCGA, The Cancer Genome Atlas; KIRC, kidney renal clear cell carcinoma; ROC, Receiver Operating Characteristic; lncRNA, long non-coding RNA; TIC, tumor-infiltrating immune cells.
Figure 2Network of lncRNAs with co-expression autophagy genes in KIRC (kidney renal clear cell carcinoma). (A) The red ellipse indicates lncRNA. The blue ellipse indicates autophagy mRNA. The lines between them indicate the co-expression relationship. (B) Sankey diagram. (Left column: autophagy-related mRNAs; middle column: the lncRNAs; right column: the risk type).
Figure 3Survival analyses of 17 autophagy-related lncRNA. The top three survival curves are the survival analyses of protective lncRNAs, and higher expression predicts a higher survival rate. The curves under them are the survival analyses of risky lncRNAs for KIRC patients, and higher expression leads to shorter survival time.
Figure 4Prognosis model basing on risk signature. (A) The survival analysis relying on risk score. (B) Distributions of 17 lncRNA expression, survival status, and risk score for patients in high and low-risk groups. (C) The clinical variables dependent receiver operating characteristic (ROC) analyses. (D) Univariate Cox analysis. (E) Multivariate Cox analysis.
Univariate Cox analysis of characteristics and risk score in KIRC
| ID | B | SE | z | HR | HR.95L | HR.95H | P value |
|---|---|---|---|---|---|---|---|
| Age | 0.023401 | 0.009062 | 2.582371 | 1.023677 | 1.005656 | 1.042021 | 0.009812** |
| Gender | 0.017341 | 0.213742 | 0.081132 | 1.017492 | 0.669258 | 1.546923 | 0.935337 |
| Grade | 0.757602 | 0.143102 | 5.294148 | 2.133156 | 1.61144 | 2.823781 | 1.20E-07*** |
| Stage | 0.59752 | 0.097529 | 6.126595 | 1.817605 | 1.501353 | 2.200474 | 8.98E-10*** |
| T | 0.614276 | 0.119009 | 5.161601 | 1.848318 | 1.463781 | 2.333873 | 2.45E-07*** |
| M | 1.391904 | 0.222367 | 6.259497 | 4.022501 | 2.601461 | 6.219781 | 3.86E-10*** |
| N | 1.110114 | 0.336707 | 3.296975 | 3.034706 | 1.568596 | 5.871135 | 0.000977*** |
| Risk score | 0.106298 | 0.015117 | 7.031483 | 1.112153 | 1.079684 | 1.145598 | 2.04E-12*** |
**, P<0.01; ***, P<0.001. KIRC, kidney renal clear cell carcinoma; SE, standard error; HR, hazard ratio.
Multivariate Cox analysis of characteristics and risk score in KIRC
| ID | B | SE | z | HR | HR.95L | HR.95H | P value |
|---|---|---|---|---|---|---|---|
| Age | 0.037606 | 0.010293 | 3.653502 | 1.038322 | 1.017585 | 1.059482 | 0.000259*** |
| Gender | 0.262189 | 0.228932 | 1.145275 | 1.299773 | 0.829852 | 2.035796 | 0.252095 |
| Grade | 0.269428 | 0.172746 | 1.559684 | 1.309216 | 0.93319 | 1.836761 | 0.118835 |
| Stage | 0.416601 | 0.264258 | 1.57649 | 1.516797 | 0.903629 | 2.546036 | 0.114913 |
| T | −0.14512 | 0.250034 | −0.5804 | 0.86492 | 0.529843 | 1.411903 | 0.561648 |
| M | 0.509551 | 0.416789 | 1.222565 | 1.664544 | 0.735401 | 3.767613 | 0.221494 |
| N | 0.428635 | 0.362005 | 1.184059 | 1.535161 | 0.755118 | 3.120992 | 0.23639 |
| Risk score | 0.084718 | 0.018718 | 4.526048 | 1.088411 | 1.049204 | 1.129082 | 6.01E-06*** |
***, P<0.001. KIRC, kidney renal clear cell carcinoma; SE, standard error; HR, hazard ratio.
Correlations between risk score signature and clinical features in the TCGA cohort
| Clinical | Group | n | Risk score | |||
|---|---|---|---|---|---|---|
| Mean | SD | t | P | |||
| Age | ≤65 | 155 | 1.977 | 4.47 | 0.614461 | 0.54 |
| >65 | 91 | 1.719 | 2.088 | |||
| Gender | Female | 97 | 1.803 | 2.73 | −0.28856 | 0.773 |
| Male | 149 | 1.933 | 4.316 | |||
| Grade | G1-2 | 109 | 0.973 | 0.87 | −3.84431 | 0.0001*** |
| G3-4 | 137 | 2.605 | 4.873 | |||
| Stage | Stage I-II | 133 | 1.036 | 0.978 | −3.64565 | 0.0001*** |
| stage III-IV | 113 | 2.878 | 5.294 | |||
| T | T1-2 | 145 | 1.098 | 1.045 | −3.40555 | 0.001** |
| T3-4 | 101 | 3.007 | 5.566 | |||
| M | M0 | 205 | 1.463 | 1.899 | −2.0149 | 0.051 |
| M1 | 41 | 3.976 | 7.94 | |||
| N | N0 | 232 | 1.659 | 3.442 | −2.27093 | 0.04* |
| N1-3 | 14 | 5.581 | 6.406 | |||
*, P<0.05; **, P<0.01; ***, P<0.001.
Figure 5Gene set enrichment analysis (GSEA) of risk signature.
Gene set enrichment analysis (GSEA) results based on the risk signature of 10 autophagy related lncRNAs
| Go name | Size | NES | NOM p-val | FDR q-val | FWER p-val | LEADING EDGE |
|---|---|---|---|---|---|---|
| Regulatory T cell differentiation | 31 | 2.293 | 0 | 0 | 0 | Tags =71%, List =11%, Signal =79% |
| Positive regulation of interferon gamma production | 64 | 2.235 | 0 | 0 | 0 | Tags =55%, List =13%, Signal =63% |
| Interferon gamma production | 108 | 2.199 | 0 | 0 | 0 | Tags =47%, List =15%, Signal =55% |
| Regulation of humoral immune response | 130 | 2.056 | 0 | 6.06E-04 | 0.015 | Tags =77%, List =34%, Signal =116% |
| B cell mediated immunity | 208 | 2.055 | 0 | 5.55E-04 | 0.015 | Tags =59%, List =26%, Signal =80% |
| Selective autophagy | 47 | −2.481 | 0 | 0 | 0 | Tags =49%, List =10%, Signal =54% |
| Regulation of macroautophagy | 168 | −2.523 | 0 | 0 | 0 | Tags =48%, List =11%, Signal =54% |
| Macroautophagy | 290 | −2.549 | 0 | 0 | 0 | Tags =48%, List =13%, Signal =54% |
| Process utilizing autophagic mechanism | 482 | −2.579 | 0 | 0 | 0 | Tags =45%, List =13%, Signal =51% |
| Positive regulation of autophagy | 114 | −2.584 | 0 | 0 | 0 | Tags =50%, List =12%, Signal =56% |
NES, normalized enrichment score; FDR, false discovery rate; FWER, family wise-error rate; NOM p-val, normal P value.
Figure 6Identification of lncRNAs related tumor-infiltrating immune cells in ccRCC tumor tissues. (A) The landscape of immune cell infiltration of KIRC patients in the TCGA cohort. (B) The correlation between 22 immune cells where red represented the negative correlation while blue represented the positive correlation. Difference test and correlation test were performed for each lncRNA respectively, and we showed SNHG15 as an example (C,D). (C) Red represented high SNHG15 group and green represented low SNHG15 group. (D) R>0 represented positive correlation between immune cells infiltration and SNHG15 expression. Conversely, R<0 represented negative correlation. (E,F) The results of difference test and correlation test for each autophagy-related lncRNA. (G) Intersection of the above tests’ results. Diff, different; Cor, correlation.